Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06073886 · ClinicalTrials.gov registry record · Phase 2

Personalized Brain Stimulation to Treat Chronic Concussive Symptoms

A Phase 2 study of Anxiety and Mild Traumatic Brain Injury, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Phase 2
Development phase
75
Enrollment target
1
Study location

NCT06073886: Recruiting Phase 2 study of Anxiety and Mild Traumatic Brain Injury, sponsored by University of California, Los Angeles.

NCT06073886 is a Phase 2 study of Anxiety and Mild Traumatic Brain Injury that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 75 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06073886, a Phase 2 study of Anxiety and Mild Traumatic Brain Injury, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Phase 2
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury. These symptoms can interfere with daily functioning, causing difficulty returning to physical activity, work, or school. Previous concussion therapies have not been personalized nor involved direct treatments to the brain itself. The treatment being tested in the present study is a noninvasive, personalized form of brain stimulation, called transcranial magnetic stimulation (TMS). The investigators intend to answer the questions: 1. Does personalized TMS improve brain connectivity after concussion? 2. Does personalized TMS improve avoidance behaviors and chronic concussive symptoms? 3. Do the improvements last up to 2 months post-treatment? 4. Are there predictors of treatment response, or who might respond the best? Participants will undergo 14 total visits to University of California Los Angeles (UCLA): 1. One for the baseline symptom assessments and magnetic resonance imaging (MRI) 2. Ten for TMS administration 3. Three for post-treatment symptom assessments and MRIs Participants will have a 66% chance of being assigned to an active TMS group and 33% chance of being assigned to a sham, or inactive, TMS group. The difference is that the active TMS is more likely to cause functional changes in the brain than the inactive TMS.

Primary Outcome

Using resting-state functional magnetic resonance connectivity in the target frontoamygdala circuit

Conditions Studied

Anxiety Mild Traumatic Brain Injury Headache Concussion, Brain Post-Concussion Syndrome Dizziness Head Injury Dysautonomia Cognitive Symptom Irritability; Syndrome

Interventions

  • DEVICE Active cTBS
  • DEVICE Inactive/Sham cTBS
  • BEHAVIORAL Imaginal exposure

Study Locations (1)

California

  • UCLA - Westwood, Los Angeles

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2024-03-06
Est. Completion 2027-01
Phase Phase 2
University of California, Los Angeles

897 total trials

What NCT06073886 shows while recruiting

NCT06073886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (83% lower).

The record links to 10 conditions, with Anxiety appearing as the primary indexed condition, and to 3 interventions - of which Active cTBS is the first listed.

NCT06073886 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06073886 about?

NCT06073886 is a clinical study titled "Personalized Brain Stimulation to Treat Chronic Concussive Symptoms". The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occ...

What is the current status of trial NCT06073886?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2024-03-06. Estimated completion is 2027-01.

What conditions does trial NCT06073886 study?

This clinical trial studies the following conditions: Anxiety, Mild Traumatic Brain Injury, Headache, Concussion, Brain, Post-Concussion Syndrome.

What interventions are being tested in trial NCT06073886?

The interventions under investigation include: Active cTBS (DEVICE), Inactive/Sham cTBS (DEVICE), Imaginal exposure (BEHAVIORAL).

Who is sponsoring clinical trial NCT06073886?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06073886 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06073886's enrollment target sits among peer trials

75 203rd of 364 higher than 159 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06073886

Source: ClinicalTrials.gov NCT06073886, the US trial registry maintained by the National Library of Medicine. NCT06073886 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.